Elli Papaemmanuil: Overview
We conduct research at three levels. Firstly we perform systematic genome profiling of large (>1000) and well-annotated patient cohorts to characterize genetic and clinical inter-relationships. We use advanced statistical modeling to study genotype-phenotype and genotype-outcome relationships as a framework for the development of molecularly guided clinical decision support algorithms to support diagnosis and prognostication of cancer patients. Such population based analysis, enable us to identify genotype combinations that are critical to disease biology, or that associate strongly with clinical presentation, response to treatment and overall survival. These studies empower our second level research. We use population data to characterize disease associated, outcome defining and treatment informing genotypes. We select representative samples for detailed molecular phenotyping using integrative genomic and cell based assays to single cell characterizations. Last, we perform detailed clonal heterogeneity tracking studies. We profile temporally as well as spatially separated samples (diagnosis, pre-treatment, post treatment) to quantify changing clonal phylogenies, during disease progression, or in response to therapeutic intervention.
We are also driving the Pediatrics Precision Medicine Initiative for the Department of Pediatrics, and support clinical translational research for the Center for Heme Malignancies at MSK.
We benefit from a fully resourced computational and research environment. We have access to state of the art computing and laboratory facilities to support truly ambitious and innovative research.
Join us: We are looking for inspiring, motivated individuals to join our team, challenge our current understanding of cancer biology and help make new discoveries that will inform cancer care and improve patient outcomes.